According to a study, patients with thyroid eye disease treated with the minimally invasive insulin-like growth factor I blocking antibody teprotumumab saw improvements in their symptoms, appearance, and quality of life.
Patients with thyroid eye disease who used the minimally invasive insulin-like growth factor I blocking antibody, teprotumumab, experienced improvement in their symptoms, appearance and quality of life, according to a study recently published in the New England Journal of Medicine.